ホーム › 非小細胞肺癌 › オクラホマ › Oklahoma City
Oklahoma City、OKにおける非小細胞肺癌の臨床試験
Oklahoma Cityとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する28件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of Oklahoma, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
被験者募集中第3相
- Local Institution - 0418, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
被験者募集中第2/3相
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- University of Oklahoma, Oklahoma City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- OU Health Stephenson Cancer Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- University of Oklahoma - Health Sciences Center, Oklahoma City
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
被験者募集中観察研究
- Mercy Hospital - OKC, Oklahoma City
Study of XB010 in Subjects With Solid Tumors
被験者募集中第1相
- Stephenson Cancer Center, Oklahoma City
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
被験者募集中第1相
- OU Stephenson Cancer Center, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
被験者募集中第1/2相
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Mercy Hospital Oklahoma City, Oklahoma City
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Hightower Clinical, Oklahoma City
- Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
被験者募集中第1相
- University of Oklahoma, Oklahoma City
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Oklahoma Cityにおける他の研究
- 卵巣がん28件の研究
- 子宮内膜がん25件の研究
- 大腸癌22件の研究
- 前立腺がん21件の研究
- 肺がん19件の研究
- 乳がん17件の研究
- 転移性癌16件の研究
- がん（全種類）14件の研究
- 急性骨髄性白血病14件の研究
- 頭頸部扁平上皮癌13件の研究
- 膀胱癌11件の研究
- 膵臓がん11件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。